Hint mode is switched on Switch off
For swift navigation between sections

Daiichi Sankyo
LEI 353800XGIU2IHQGC9504

PDF download

Choose all Reset all
Download Cancel
Organization name
Daiichi Sankyo Company, Limited
Country name
Japan
Country of registration
Japan
Industry
Pharmaceutical Preparation and Biotechnology
Bond debt
682 mln USD

explore the most comprehensive database

900 000

bonds globally

Over 400

pricing sources

80 000

stocks

116 000

ETF & Funds

track your portfolio in the most efficient way

  • Bond Search
  • Watchlist
  • Excel ADD-IN
Get access
×

— Are you looking for the complete & verified bond data?

— We have everything you need:

full data on over 900 000 bonds, 80 000 stocks, 116 000 ETF & Funds; powerful bond screener; over 350 pricing sources among stock exchanges & OTC market; ratings & financial reports; user-friendly interface; available anywhere via Website, Excel Add-in and Mobile app.

Register
×

Why

You will have detailed descriptive & pricing data for 650K bonds, 76K stocks, 8K ETFs
Get full access to the platform from any device & via Cbonds app
Enhance your portfolio management with Cbonds Excel Add-in
Build yield maps, make chart comparison within a click
Don't wait any longer — start using Cbonds today! Register

Latest data on

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

Daiichi Sankyo Company, Limited (第一三共株式会社 Daiichi Sankyō Kabushiki-kaisha?) is a global pharmaceutical company and the second largest pharmaceutical company in Japan. It achieved JPY 1,148.2 billion in revenue in 2013. The company owns the American biotechnology company Plexxikon, the German biotechnology company U3 Pharma and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.

Awards

News

31/01/2025 Daiichi Sankyo's Nine-Month Profit Jumps 28%
13/01/2025 Daiichi Sankyo Buys Back 2 Million Shares
03/11/2024 Daiichi Sankyo Buys Back 5.6 Million Shares in October
02/09/2024 Daiichi Sankyo Repurchases 4.9 Million Shares for 27.84 Billion Yen
01/08/2024 Daiichi Sankyo's Attributable Profit Gains Nearly 50% in Fiscal Q1; Shares Climb Over 5%
All organization news

Documentation

Stocks

Latest issues

Show all

Public debt by currencies

Show more Hide

Codes

  • LEI
    353800XGIU2IHQGC9504
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001340156
Registration is required to get access.